LYRA - Lyra Therapeutics GAAP EPS of -$1.83 misses by $0.05 revenue of $1.36M
2023-03-29 16:56:32 ET
- Lyra Therapeutics press release ( NASDAQ: LYRA ): FY GAAP EPS of -$1.83 misses by $0.05 .
- Revenue of $1.36M (+369.0% Y/Y).
- Cash, cash equivalents and short-term investments were $97.9 million as of December 31, 2022, compared to $109.6 million as of September 30, 2022.
- Research and development expenses for the fourth quarter and full year ended December 31, 2022 were $9.5 million and $38.8 million, respectively, compared to $10.3 million and $29.7 million for the same periods in 2021.
- The Company recorded an impairment charge of $1.3 million related to long-lived assets for the year ended December 31, 2022.
- Net loss for the fourth quarter and full year ended December 31, 2022 was $14.2 million and $55.3 million, respectively, compared to $13.6 million and $43.5 million for the same periods in 2021.
For further details see:
Lyra Therapeutics GAAP EPS of -$1.83 misses by $0.05, revenue of $1.36M